| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 455.56% | BMO Capital | $25 → $24 | Maintains | Outperform |
| 10/05/2023 | 455.56% | Maxim Group | → $24 | Initiates Coverage On | → Buy |
| 09/06/2023 | 362.96% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/18/2023 | 501.85% | JonesTrading | → $26 | Initiates Coverage On | → Buy |
| 08/11/2023 | 362.96% | HC Wainwright & Co. | $21 → $20 | Reiterates | Buy → Buy |
| 06/02/2023 | 478.7% | Oppenheimer | → $25 | Initiates Coverage On | → Outperform |
| 05/08/2023 | 478.7% | BMO Capital | → $25 | Initiates Coverage On | → Outperform |
| 05/02/2023 | 455.56% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 04/20/2023 | 455.56% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/12/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 12/12/2022 | 293.52% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 12/12/2022 | 478.7% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
What is the target price for Acrivon Therapeutics (ACRV)?
The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by BMO Capital on November 10, 2023. The analyst firm set a price target for $24.00 expecting ACRV to rise to within 12 months (a possible 455.56% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?
The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by BMO Capital, and Acrivon Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?
While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a maintained with a price target of $25.00 to $24.00. The current price Acrivon Therapeutics (ACRV) is trading at is $4.32, which is out of the analyst's predicted range.